Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis?∗
Copyright policy )Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis?∗
In 2001, when Morice et al. [(1)][1] presented the initial results of RAVEL (The Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions), showing 0% angiographic restenosis 6 months after implantation
- Imperial College London United Kingdom
- EMO GVM Centro Cuore Columbus Italy
Male, Sirolimus, percutaneous coronary intervention, Drug-Eluting Stents, drug-eluting stent(s), in-stent restenosis, Coronary Restenosis, drug-eluting balloon, Humans, Female, Angioplasty, Balloon, Coronary, Cardiology and Cardiovascular Medicine, Immunosuppressive Agents
Male, Sirolimus, percutaneous coronary intervention, Drug-Eluting Stents, drug-eluting stent(s), in-stent restenosis, Coronary Restenosis, drug-eluting balloon, Humans, Female, Angioplasty, Balloon, Coronary, Cardiology and Cardiovascular Medicine, Immunosuppressive Agents
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!